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ABSTRACT
Introduction: Molluscum contagiosum is a
viral infection of the skin that is spread from
direct contact, either via person to person by
touching affected lesions or innocuously via
fomites. The condition is often socially
stigmatizing, motivating patients to seek
treatment. There are many anecdotal
remedies, but none have been overwhelmingly
effective in controlled clinical trials.
Case Report: A 16-year-old girl presented with
approximately 75 lesions on her inner thighs as
a result of friction from an athletic uniform. She
tried over-the-counter antibiotic ointment and
topical steroids for several weeks without
improvement, and was concerned at the rate
of spread of the lesions, along with the social
implications.
Conclusion: The topical povidone-iodine/
dimethylsulfoxide system is very effective in
eradicating molluscum contagiosum. This
novel combination warrants further
investigation in randomized, controlled trials




Molluscum contagiosum (MC) is a viral
infection of the skin caused by a DNA
poxvirus called the molluscum contagiosum
virus. MC is spread from direct contact, either
via person to person by touching affected
lesions or innocuously via fomites. The skin
infection is most common in children and
sexually active adults. MC can affect any area
of the skin, and remains infectious until the
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lesions have resolved. Most lesions will resolve
without treatment, with the average length of
infection lasting between 6 and 18 months [1].
The condition is often socially stigmatizing and
patients subsequently seek treatment. Though
there are many anecdotal remedies, none have
been shown to be universally effective as a
take-home prescription option in controlled
clinical trials.
CASE REPORT
A 16-year-old girl presented with a 4-week
history of an asymptomatic rash on the
superior medial thighs. It started as several
lesions on the right thigh and over the next
several weeks spread towards the knee and
the adjacent thigh. She admitted to
continuous friction in the area from a field
hockey uniform. Physical examination
revealed approximately 75 skin colored
umbilicated papules, with several
demonstrating varying degrees of
inflammation. Over-the-counter topical
antibiotic ointment and topical steroids
were tried for duration of 2 weeks prior to
the visit without improvement. A diagnosis
of MC was made.
The patient was given a topical solution of
1% povidone-iodine (PVP-I) in a
dimethylsulfoxide (DMSO) vehicle that was
prescribed from a licensed compounding
pharmacy. The solution was applied twice
daily. At the 3-week follow-up visit,
approximately half of the lesions had resolved
and no new lesions had appeared. By 6 weeks
there was complete resolution. Besides mild
dryness at the application site, the patient
denied any side effects from treatment.
Informed consent was obtained from all
patients for being included in the study.
DISCUSSION
MC, although medically benign, is a readily
spread viral infection that can be cosmetically
disfiguring, prompting many to seek treatment.
The only FDA-approved treatment is the
in-office application of cantharidin, which
works mechanistically via selective
acantholysis intraepidermally, inducing a
blister at the involved skin site [2, 3]. Local
destruction can also be achieved off label via
curettage, laser, cryotherapy or needle
extraction, but these are painful and not
tolerated well by children. Lesion eradication
may also be chemical (trichloroacetic acid,
tretinoin), or immunologic (imiquimod),
inciting an inflammatory response which
upregulates the immune system to clear the
infection [4]. Topical cidofovir has been used in
the immunosuppressed population, but has not
been systemically studied in the general
population [5, 6]. This is the first case report of
a broad-spectrum anti-microbial demonstrating
efficacy in this common condition.
PVP-I is used primarily in dermatology as a
surgical preparation as it has been recognized as a
broad spectrum, resistance-freebiocidal agent for
many years. Though incompletely understood, it
is likely that free iodine poisons electron
transport, inhibits cellular respiration,
destabilizes membranes, inhibits protein
synthesis and denatures nucleic acids. Although
PVP-I kills microorganisms including bacteria,
viruses, yeasts, molds, fungi and protozoa, it has
scarcely been used for purposes outside of skin
asepsis in dermatology [7].
DMSO is a very effective pharmaceutical
vehicle, greatly enhancing percutaneous
penetration when used in combination with
other substances. DMSO facilitates diffusion
through the stratum corneum, triggers the
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formation of drug deposition in the dermis, and
promotes transport into local blood vessels [8].
Compounded PVP-I in a DMSO vehicle is
commonly used in our practice for a variety of




We have had remarkable success with this novel
combination. The lack of prescription
FDA-approved therapies presents both a clinical
dilemma for the practitioner and the patient as
current at-home treatments are used primarily in
the pediatric population. The topical
povidone-iodine/DMSO system we have
pioneered has been very effective in eradicating
widespread disease. This novel combination
warrants further investigation in randomized,
controlled trials to further elucidate its clinical
utility with the aim of enabling an eventual FDA
approval for this currently unmet need.
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